<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278056</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670EDE08T</org_study_id>
    <nct_id>NCT01278056</nct_id>
  </id_info>
  <brief_title>The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis</brief_title>
  <acronym>DEFINE</acronym>
  <official_title>The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis (NASH) - a Prospective Open Label Phase I/II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crolll Gmbh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Estimate, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Crolll Gmbh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/II open-label uncontrolled, prospective study to assess the clinical and
      biological effects of Deferasirox (ICL 670, Exjade®) in patients with NASH and increased iron
      storage / distribution of iron on liver function and liver histology.

      NASH is defined clinically and histologically by elevated liver enzymes, signs of hepatic
      steatosis on ultrasound and magnetic resonance imaging, impaired liver function as expressed
      by functional breath tests, and significantly altered liver histology.

      Patients will be treated in a phase I and phase II part for either 12 or 48 weeks.

      Both study parts have different endpoints: in phase I the side effect profile will be
      evaluated while in phase II the therapeutic response will be tested. Accordingly, measures
      will be different.

      Approximately 10 patients in phase I and 50 patients in phase II will be enrolled according
      to sample size calculations.

      The design is an &quot;adaptive&quot; Two-stage design, allowing to minimize the number of patients
      included into the trial as well as to introduce corrections for the second stage.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of deferasirox in all patients (Phase I)</measure>
    <time_frame>Phase I: 12 weeks of treatment</time_frame>
    <description>Safety and tolerability assessments will consist of evaluating (serious) adverse events, laboratory parameters including hematology, chemistry; vital signs and physical examinations according to CTC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in liver histology in all patients (Phase II)</measure>
    <time_frame>Phase II: 48 weeks of treatment</time_frame>
    <description>A decrease in the NASH activity score (NAS) of ≥1 compared to baseline will be classified as response, an unchanged score or an increase in NAS will be judged as non-response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: e.g. changes in liver enzymes, serum ferritin, and hemoglobin levels</measure>
    <time_frame>Phase I: 12 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: e.g. changes in MRI and histology based assessment of hepatic steatosis, fibrosis and iron content</measure>
    <time_frame>Phase II: 48 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <condition>Increased Iron Storage / Disturbed Distribution</condition>
  <arm_group>
    <arm_group_label>Exjade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exjade</intervention_name>
    <description>Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.</description>
    <arm_group_label>Exjade</arm_group_label>
    <other_name>Deferasirox, ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (shortened):

          -  Patients with elevated liver enzymes

          -  Elevated serum ferritin (females &gt; 300 ng/ml, males &gt; 450 ng/ml)

          -  Liver Histology consistent with a diagnosis of NASH

        Exclusion Criteria (shortened):

          -  Alcohol intake &gt; 140 g/week

          -  Established liver cirrhosis Child Pugh B or C

          -  Copresence of other causes of chronic liver disease

          -  Anemia &lt; 10 g/dl

          -  Any elevation of liver enzymes &gt; 5 ULN (ALAT, ASAT, g-GT), &gt; 2.5 ULN (other), &gt; 1.5
             (Bilirubin)

          -  Serum creatinine &gt; 1.4 mg/dl or Ccr &lt; 60 ml/min

          -  Hemochromatosis

          -  Known allergy or contraindication to the administration of Deferasirox

          -  Sexually active pre-menopausal female patients who are unable to use a highly
             effective method of birth control. An exception is made for those who have undergone
             clinically documented total hysterectomy and/or oophorectomy, tubal ligation.

          -  Patients with impaired coagulation

          -  History of blood transfusion during the 6 months prior to study entry

          -  Oral iron supplementation within the last 4 weeks of study entry

          -  Treatment with phlebotomy within 2 weeks of screening visit

          -  Desferal treatment within 1 month of the screening visit

          -  Patients currently or previously treated with deferiprone or Deferasirox

          -  Presence of a surgical or medical condition that might significantly alter the
             absorption, distribution, metabolism or excretion of any study drug

          -  Positive HIV serology

          -  Patients with active inflammatory diseases that may interfere with the accurate
             measurement of serum ferritin

          -  Patients with a diagnosis of a clinically relevant cataract or a previous history of
             clinically relevant ocular toxicity related to iron chelation

          -  Pregnant or breast feeding patients

          -  Patients treated with systemic investigational drug within 4 weeks prior or with
             topical investigational drug within 7 days prior to the screening visit

          -  Medications with proven or suspected influence on NASH such as glitazones, statins, or
             metformin are no exclusion criteria for study entry (insulin is not regarded to
             interfere with NASH).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Treiber, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Zollernalbklinikum</name>
      <address>
        <city>Balingen/Hechingen</city>
        <zip>72336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité, Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J. W. Goethe-Universität, Med. Klinik I</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle, Klinik &amp; Poliklinik für Innere Medizin I</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg, Klinik für Gastroenterologie, Hepatologie und Infektiologie</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz, I. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Med. I</name>
      <address>
        <city>Regensburg</city>
        <zip>93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik IV</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2011</study_first_submitted>
  <study_first_submitted_qc>January 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2011</study_first_posted>
  <last_update_submitted>July 19, 2012</last_update_submitted>
  <last_update_submitted_qc>July 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic steatohepatitis (NASH) and increased iron storage / disturbed distribution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

